Glenmark Therapeutics Inc., USA (Glenmark) has launched Olopatadine hydrochloride ophthalmic solution USP, 0.1% (OTC); compare to the active ingredient in Pataday twice daily relief.
According to Nielsen syndicated data for the latest 52 weeks’ period ending July 13, 2024, the Pataday twice daily relief (OTC) market achieved annual sales of approximately $26.4 million.
Commenting on the launch, Fabio Moreno, head – OTC sales & marketing, Glenmark Pharmaceuticals Inc. said, “We are excited to announce the launch of Olopatadine ophthalmic solution USP, 0.1%, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers.”
Glenmark Pharmaceuticals Ltd. is a research-led, global pharmaceutical company, having a presence across branded, generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!